Trials / Recruiting
RecruitingNCT06807294
Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- Sponsor
- Dana-Farber Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).
Detailed description
This is a prospective, randomized, waitlist-controlled pilot trial to examine the suitability of the virtual Tai Chi program in cancer survivors with CIPN. Tai Chi is a mind-body practice that involves gentle body movements, meditation, and breathing techniques. It has proven to be effective in enhancing balance control and relieving musculoskeletal pains. This study randomly assigns cancer survivors with CIPN with self-perceived balance difficulties to one of two groups: Group A Tai Chi Group versus Group B Waitlist Group. Randomization means a participant is placed into a study group by chance. The research study procedures including screening for eligibility, questionnaires, and sensory and functional testing. Participation in this study is expected to last for up to 12 weeks. It is expected that about 21 people will take part in this research study.
Conditions
- Chemotherapy Induced Peripheral Neuropathy (CIPN)
- Peripheral Neuropathy Due to Chemotherapy
- Peripheral Neuropathies
- Neuropathy
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Tai Chi Program | 12-week virtual Tai Chi program with experienced Tai Chi instructor. Sessions will be conducted via the HIPPA-compliant teleconference platform, Zoom. |
Timeline
- Start date
- 2026-01-16
- Primary completion
- 2026-08-31
- Completion
- 2026-10-31
- First posted
- 2025-02-04
- Last updated
- 2026-01-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06807294. Inclusion in this directory is not an endorsement.